Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Severe Acute Respiratory Syndrome 1Mastocytosis 1Lymphoma 1Hypersensitivity 1Hematopoietic and Lymphatic System Neoplasm 1COVID-19 1

Interventions

Specimen Handling 3COVID-19 Vaccines 3Blood Specimen Collection 3Surveys and Questionnaires 2Standard of Care 2Practice Guidelines as Topic 2COH04S1 COVID-19 vaccine 22019-nCoV Vaccine mRNA-1273 2sotrovimab 1ciclesonide 1Therapeutics 1Telemedicine 1Sodium Chloride 1Patient Reported Outcome Measures 1Observation 1Nutritional Status 1Niclosamide 1NVX-CoV2373 adjuvated lipid nanoparticle 1IMM-101 1Exercise Therapy 1Exercise 1Educational Status 1Diagnostic Tests, Routine 1Data Collection 1CVnCoV COVID-19 vaccine 1BNT162 Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × BNT162 Vaccine × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡